

BRINGING CHANGE FOR FEMALE CANCERS

context

Corporate Presentation
April 2022

Forward Looking Statement

Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company's current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company's actual activities or results to differ significantly from those expressed in any forward-looking statement. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "plan", "predict", "expect," "estimate," "anticipate," "intend," "goal," "strategy," "believe," "could", "would", "potential", "project", "continue" and similar expressions and variations thereof.

Forward-looking statements may include statements regarding the Company's business strategy, cash flows and funding status, potential growth opportunities, clinical development activities, the timing and results of preclinical research, clinical trials and potential regulatory approval and commercialization of product candidates.

Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in documents the Company has filed with the SEC. These forward-looking statements speak only as of the date of this presentation and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Certain information contained in this presentation may be derived from information provided by industry sources. The Company believes such information is accurate and that the sources from which it has been obtained are reliable. However, the Company cannot guarantee the accuracy of, and has not independently verified, such information.

Trademarks: The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

Company Highlights


Focus on Women's Oncology	→ Unmet clinical need in breast, ovarian, and endometrial cancers
Lead Asset: ONA-XR oral PR antagonist	 → Progesterone receptor (PR) oncogenic signaling is associated with breast, ovarian, and endometrial cancer¹ → Onapristone is a progesterone receptor (PR) antagonist that suppresses PR oncogenic signaling² → Onapristone extended release (ONA-XR) is a proprietary, oral, extended-release form of onapristone → ONA-XR has been administered in over 128 subjects-to-date → ONA-XR being evaluated in four ongoing mid-stage clinical trials
Second Asset: CLDN6 x CD3 bispecific antibody	 → Claudin 6 (CLDN6) is a protein expressed in ovarian and endometrial cancer, but not in normal adult tissues → Developing a highly selective CLDN6 x CD3 bispecific antibody
Path Forward	 → Multiple clinical inflection points in 2022 → Cash runway into 2024

Pipeline

Cancer	Clinical Indication	Research Phase 1	Phase 2	Phase 3	Upcoming Milestones	FDA Fast Track	
ONA-XR (PR a	ONA-XR (PR antagonist) ¹						
Breast	1L ER+,PR+,HER2- ctDNA ^{high}	Phase 1b/2 Trial			Phase 1b data Mid 2022		
Cancer	2L/3L ER+,PR+,HER2- Post-CDK4/6 inhibitor	Phase 2 Trial			Preliminary data 2H 2022		
Ovarian Cancer	Recurrent PR+ Granulosa Cell	Phase 2 Trial			Preliminary data 2H 2022	\bigcirc	
Endometrial Cancer	Recurrent PR+ Endometrioid	Phase 2 Trial			Preliminary data Mid 2022		
CLDN6xCD3 bispecific antibody							
	Ovarian & Endometrial Cancer				IND enabling studies 2H 2022		


Market Opportunity

- We target large, underserved markets
- Within the G7 countries, over 362,000 patients are living with metastatic breast, ovarian, or endometrial cancer



Prevalence of Metastatic Female Hormone-Driven Cancers in G7 Countries (EU5, Japan, US)

Experienced Team



Focus on Execution

- We believe that clinical development of ONA-XR is primarily a function of exacting clinical execution
- Our CMO led the clinical development of multiple blockbuster drugs for female cancers, including Kisqali, Arimidex, and Afinitor
- Our management team is supported by a Board with strong public company operating and governance experience

Lead Asset

ONA-XR Progesterone Receptor Antagonist

Context


7 Nasdaq: CNTX

Onapristone Extended Release (ONA-XR)

Mechanism of Action	 → Onapristone is a progesterone receptor (PR) antagonist that suppresses PR oncogenic signaling → PR oncogenic signaling is associated with breast, ovarian, and endometrial cancer → Onapristone is the only known clinical-stage full PR antagonist
Market Opportunity	\rightarrow Breast, ovarian, and endometrial cancers are large and growing markets \rightarrow Up to 70% of these cancer patients have progesterone receptor positive disease
Dosing and Administration	→ ONA-XR is an extended-release (XR) tablet form of onapristone (ONA) → 50 mg tablets administered orally twice per day
Focus on Clinical Execution	 → ONA-XR has been administered in over 128 subjects-to-date → ONA-XR is currently the subject of three ongoing Phase 2 trials and one ongoing Phase 1b/2 trial → Preliminary clinical data in 2022, with more advanced data in 2023
Intellectual Property	\rightarrow IP protection through at least 2034

Clinical Development Strategy

Blocking cancer growth by combining antiestrogen and antiprogestin therapies




ONA-XR Evaluation in Breast Cancer Trials

Treatment Line	Context Trial	Clinical Collaborator	Trial Status	Estimated Patients (US) ⁴	Standard of Care (SOC)	Medical Need
Adjuvant (after primary disease treatment)	Window of Opportunity ¹		Completed	>>250,000	Antiestrogen	Enhance antiestrogen potency
First-Line Metastatic	1L ER+,PR+,HER2- (ctDNA ^{high}) ²	Memorial Sloan Kettering Cancer Center	Enrolling Patients	75,000	Antiestrogen + CDK4/6i	Treat patients who are at high risk of early progression
Second / Third Line Metastatic	2L/3L ER+,PR+,HER2- (post-CDK4/6i) ³	Carbone Cancer Center UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH	Enrolling Patients	35,000	Fulvestrant or Fulvestrant + PI3Ka	Improve response rate and progression free survival

Developing ONA-XR as an Add-on to Antiestrogen Therapy Across Treatment Lines

(1) NCT04142892; (2) NCT04872608; (3) NCT04738292(4) Source: secondary epidemiologic estimates, 2020 estimates

ONA-XR Evaluation in Gynecologic Trials



Developing ONA-XR as an Add-on to Antiestrogen Therapy Across Gynecologic Cancers


(1) NCT04719273; (2) NCT03909152(3) Source: secondary epidemiologic estimates, 2020 estimates

ONA-XR

ONAWA (SOLTI-1802) Preliminary Data

Context


Window of Opportunity Trial in Primary Breast Cancer



Key Eligibility Criteria

- Post-menopausal women
- Histologically confirmed
 invasive breast carcinoma
- PR+, ER+, HER2- as per local assessment
- Local Ki67 ≥15%

High PR Expression Associated with Treatment Response




ONA-XR treatment response was seen in the high PR patient population

Ki67 = marker of cell proliferation Bellet et al., San Antonio Breast Cancer Symposium 2021

ONA-XR Shifted Tumors to a More Hormone-sensitive State

A post-treatment switch to a more hormone-sensitive phenotype was observed, as shown by the increase Luminal A score at surgery (post-3 weeks of ONA-XR) and risk of recurrence (ROR) scores



The shift implies an increased chance of tumor responsiveness to combined anti-estrogen and ONA-XR therapy

Claudin 6 Program

Context

CLDN6 x CD3 Bispecific Antibody Program




Claudin-6 is a tumor-specific protein in adults



Integrating Claudin-6 binding with the CD3 T-cell engager couples immunotherapy to tumor specific targeting



Opportunity to be 1st/2nd in market based on current competition



The bispecific antibody simultaneously binds to a CLDN6expressing tumor cell and a cytotoxic T-cell. This brings the T-cell into proximity to the tumor cell. The T-cell, activated by CD3, releases cytotoxic cytokines that drive tumor cell death.

Competitive Landscape/Advantage

	Context	Xencor	BioNTech
Asset	Confidential	Confidential	BNT211
Format	CLDN6xCD3 Bispecific	CLDN6xCD3 Bispecific	CLDN6 CAR-T
Stage	Preclinical	Preclinical	Phase 1
Status	Active	Active	Active ²
Selectivity CLDN6:9	>100x	10x ¹	7x

 Based on internal studies and published data, Context anti-CLDN6 binding is at least 10x more selective vs. CLDN9 than competitive anti-CLDN6 mAbs and bispecifics

 CLDN6:CLDN9 binding selectivity is a critical safety factor for CLDN6targeted bispecific antibodies

Claudin 9 (CLDN9) is expressed in normal adult tissues, including the inner ear, olfactory epithelium, and pituitary gland. It is involved in hearing – a key reason for the importance of CLDN6:CLDN 9 selectivity.

The Company has performed head-to-head *in vitro* studies comparing BioNTech CLDN6 monoclonal antibodies. These antibodies were derived from publicly available reports published independent of the Company and may differ in material ways from the actual antibody that is in development.

Corporate

Context

Upcoming Milestones

ONA-XR	Q4 2021	1H 2022	2H 2022
Breast – Window of Opportunity data presentation	V		
Breast – mechanism of action data presentation		V	
Breast – 1L (ctDNA enriched) Phase 1b trial update			
Endometrial – Phase 2 trial update			
Breast – 2L/3L (post-CDK4/6) Phase 2 trial update			
Granulosa Cell – combination Phase 2 trial update			

Claudin 6	Q4 2021	1H 2022	2H 2022
Preclinical update		\checkmark	

Investment Highlights



Large

Unmet Need

Female Cancers



High Value Targets

> Progesterone Receptor and Claudin 6

•

Near-Term Milestones

Multiple Data Readouts in 2022



Strong Team

Deep Domain Experience, Track Record of Success



Financial Strength

Expected cash runway into 2024



BRINGING CHANGE FOR FEMALE CANCERS

context

© CONTEXT THERAPEUTICS 2022